 Home > Biochemistry News > Biotechnology News > AstraZeneca reaches deal with Ionis to develop innovative ASO therapy over $3.5 billion

AstraZeneca reaches deal with Ionis to develop innovative ASO therapy over $3.5 billion

 Last Update: 2022-02-24
 Source: Internet
 Author: User

Tags

james 1 3

modafinil drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 29, 2021, Ionis Pharmaceuticals announced the completion of a collaboration agreement with AstraZeneca on eplontersen

In ATTR patients, mutant and wild-type TTR proteins form fibrils in human tissues, which in turn disrupt normal tissue function

Globally, there are an estimated 300,000 to 500,000 ATTR-CM patients, and 1 to 40,000 ATTR-PN patients

The single-stranded DNA molecule of ASO drugs can lead to the degradation of mRNA or change the splicing of mRNA by binding to a specific RNA sequence, so as to achieve the effect of targeting the underlying disease mechanism at the mRNA level and treating the disease

▲Ionis' new generation LICA technology can deliver ASO to various organs and tissues of the human body by coupling ASO with different ligands (Image source: Ionis official website)

In addition, Ionis also expects hereditary ATTR-PN to be the first indication for eplontersen and is expected to submit a New Drug Application (NDA) to the US FDA by the end of 2022

References:

[1] Ionis And Astrazeneca Close Deal To Develop And Commercialize Eplontersen.

[2] Astrazeneca And Ionis Close Agreement To Develop And Commercialise Eplontersen.

[3] Astrazeneca And Ionis Sign Deal To Develop And Commercialise Eplontersen.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.